Therefore, we performed a prospective study of fulvestrant in combination with oral vinorelbine to evaluate the efficacy and safety of this combination in patients with HR+/HER2− advanced breast cancer, and to find whether this novel dual-therapy might further improve the prognosis of patients with advanced breast cancer receiving routine endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.